Viridian Therapeutics, Inc.

Welcome to the Viridian Therapeutics first quarter 2023 conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will be given at that time. As a reminder, this conference is being recorded. I would now like to hand the call over to Ms. Louisa Stone, Manager of Investor Relations for Viridian.

Please go ahead.

Thank you and welcome everyone to our first quarter 2023 earnings conference call. The press release reporting our financial results and corporate updates is available on the investor's page of our corporate website at www.viridiantherapeutics.com. Joining me on the call this afternoon are Scott Myers, our President and Chief Executive Officer, Christian Humer, our Chief Financial and Business Officer, Dr. Deepa Rajagopalan, our Chief Product and Strategy Officer, Dr. Tom Chula, our Chief Development Officer, and Todd James, Senior Vice President, Corporate Affairs and Investor Relations. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook in addition to regulatory, product development, and commercialization plans and research activities. These statements are subject to risks and uncertainties that could cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q and 10-K on file with the SEC. I would now like to turn the call over to Scott Myers, our President and CEO.